Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TEVA stock price vs JNPR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JNPR's multiple
Needs JNPR P/E.
Implied fair value · at TEVA's multiple
Needs TEVA P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TEVA FY 2025 (ended Dec 31, 2025) · JNPR FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
JUNIPER NETWORKS, INC. · implied price per share
Bear
$16.15
Base
$19.35
Bull
$23.51
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.23x
0.42x
Net debt / EBITDA
Leverage against operating earnings
-0.42x
1.18x
Cash and equivalents
Liquid reserves on the balance sheet
$3.56B
$1.38B
Total debt
Interest-bearing obligations outstanding
$1.82B
$2.01B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Viatris Inc
TEVA vs VTRS
Organon & Co.
TEVA vs OGN
ANI PHARMACEUTICALS INC
TEVA vs ANIP
CISCO SYSTEMS, INC.
TEVA vs CSCO
Dell Technologies Inc.
TEVA vs DELL
Palo Alto Networks Inc
TEVA vs PANW
Fortinet, Inc.
TEVA vs FTNT
VERISIGN INC/CA
TEVA vs VRSN
Match Group, Inc.
TEVA vs MTCH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe TEVA can sustain its stronger growth and margins while reducing leverage, then TEVA looks investable on quality momentum despite a not-cheap earnings multiple, because its operating performance is clearly ahead of JNPR but its balance-sheet risk remains the main constraint.
TEVA trades at 28.6x P/E and 2.3x P/S, with EV/EBITDA at 16.4x and EV/Revenue at 3.9x, while JNPR has no disclosed valuation multiples in the provided data. TEVA is also near the upper end of its historical band at $34.64 versus $31.18-$38.10, but still below the low end of its DCF range at $22.91-$31.00.
Supporting Metrics
